Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income: 2022-2024

Historic Net Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$204.7 million.

  • Day One Biopharmaceuticals' Net Income fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.38% down from last year.
  • As of FY2024, Day One Biopharmaceuticals' Net Income stood at -$204.7 million, which was down 8.38% from -$188.9 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Net Income peaked at -$142.2 million during FY2022, and registered a low of -$204.7 million during FY2024.
  • For the 3-year period, Day One Biopharmaceuticals' Net Income averaged around -$178.6 million, with its median value being -$188.9 million (2023).
  • Data for Day One Biopharmaceuticals' Net Income shows a maximum YoY crashed of 32.86% (in 2023) over the last 5 years.
  • Day One Biopharmaceuticals' Net Income (Yearly) stood at -$142.2 million in 2022, then slumped by 32.86% to -$188.9 million in 2023, then declined by 8.38% to -$204.7 million in 2024.